General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Senda Biosciences in Exclusive Global Development & Option Agreement with Nestlé Health Science

February 16, 2021
A life sciences team advises the therapeutics company in the transaction that will focus on developing novel nutritional therapies for metabolic conditions.

Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, has announced that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.

Latham & Watkins LLP represents Senda Biosciences in the transaction. The strategic collaboration was led by partner Judith Hasko, with associates Jekkie Kim and Seth Appiah-Opoku. Corporate aspects of the transaction were led by partner Peter Handrinos, with associate Samuel Niles. Advice was also provided on tax matters by partner Kirt Switzer, with associate Derek Berry; and on regulatory matters by partner Ben Haas.

    Related Capabilities